Reshma Kewalramani Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 6 days, 21 hours ago
Reshma Kewalramani has an estimated net worth of at least $112.5 million*, as of March 25, 2026. They own 138,278 shares of VRTX stock. They have sold 134,222 shares of VRTX stock since 2021, for an estimated $49.7 million.
Reshma Kewalramani $VRTX SEC Form 4 Insider Trading
Reshma Kewalramani has filed a total of 19 insider trades in $VRTX since 2021. Their most recent trade was a purchase of 4,290 shares, made on Aug 06, 2025. Their largest trade was a sale of 17,135 shares, made on Dec 15, 2023. We estimate that they now own 138,278 shares of $VRTX, worth an estimated $62.9 million.
Insider Trading at $VRTX
There have been a total of 563 insider trades reported at $VRTX since 2021, with 40,000 shares purchased and 1.1 million shares sold. The most active insider traders in $VRTX stock have been David Altshuler, Ourania Tatsis, and Bastiano Sanna. The most recent trade was a sale of 2,329 shares reported by Carmen Bozic (EVP and CMO), made on Mar 27, 2026.
History of Insider Stock Trades by Reshma Kewalramani
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
VRTX
|
Purchase | 4,290 | Aug 06, 2025 | Aug. 7, 2025, 4:23 p.m. |
|
VRTX
|
Purchase | 5,710 | Aug 06, 2025 | Aug. 7, 2025, 4:23 p.m. |
|
VRTX
|
Sale | 15,198 | Nov 08, 2024 | Nov. 12, 2024, 5:08 p.m. |
|
VRTX
|
Sale | 15,202 | Jul 30, 2024 | Aug. 1, 2024, 4:17 p.m. |
|
VRTX
|
Sale | 15,202 | Jul 22, 2024 | July 24, 2024, 4:05 p.m. |
|
VRTX
|
Sale | 1,565 | May 24, 2024 | May 29, 2024, 4:08 p.m. |
|
VRTX
|
Sale | 15,202 | May 20, 2024 | May 22, 2024, 4:21 p.m. |
|
VRTX
|
Sale | 17,135 | Dec 15, 2023 | Dec. 19, 2023, 5:15 p.m. |
|
VRTX
|
Sale | 5,098 | Dec 13, 2023 | Dec. 15, 2023, 5:23 p.m. |
|
VRTX
|
Sale | 5,097 | Nov 13, 2023 | Nov. 15, 2023, 5:16 p.m. |
|
VRTX
|
Sale | 7,828 | Jul 17, 2023 | July 18, 2023, 4:13 p.m. |
|
VRTX
|
Sale | 1,611 | Apr 27, 2023 | May 1, 2023, 4:26 p.m. |
|
VRTX
|
Sale | 38 | Apr 27, 2023 | May 1, 2023, 4:26 p.m. |
|
VRTX
|
Sale | 1,668 | Apr 27, 2023 | May 1, 2023, 4:26 p.m. |
|
VRTX
|
Sale | 10,000 | Jan 25, 2023 | Jan. 27, 2023, 5:13 p.m. |
|
VRTX
|
Sale | 11,689 | Aug 15, 2022 | Aug. 17, 2022, 5:40 p.m. |
|
VRTX
|
Sale | 11,689 | Jun 24, 2022 | June 28, 2022, 4:05 p.m. |
|
VRTX
|
Purchase | 5,757 | Aug 19, 2021 | Aug. 22, 2021, 8 p.m. |
|
VRTX
|
Purchase | 4,243 | Aug 19, 2021 | Aug. 22, 2021, 8 p.m. |
$VRTX Executives and Stock Owners with Insider Trades
-
David Altshuler, EVP, Global Research and CSO
-
Ourania Tatsis, EVP, Chief Reg. & Quality Off.
-
Bastiano Sanna, EVP, Cell & Genetic Therapies
-
Stuart A Arbuckle, EVP, COO
-
Jeffrey M Leiden, Executive Chairman
-
Charles F Jr Wagner, EVP & Chief Financial Officer
-
Reshma Kewalramani, CEO & President
-
Joy Liu, SVP, General Counsel
-
Kristen Ambrose, SVP & Chief Accounting Officer
-
Amit Sachdev, EVP Chief Patient & Ext Af Off
-
Carmen Bozic, EVP and CMO
-
Edward Morrow Iii Atkinson, EVP, Chief Technical Ops. Off.
-
Jonathan Biller, EVP and Chief Legal Officer
-
David Altshuler, EVP, Chief Scientific Officer
-
Duncan Mckechnie, EVP, Chief Commercial Officer
-
Mark E. Bunnage, EVP, Chief Scientific Officer
-
Amit Sachdev, EVP, Chief Patient Officer
-
Charles F Jr Wagner, EVP, CO & FO
-
Joy Liu, EVP and Chief Legal Officer
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.